|Day Low/High||0.20 / 0.23|
|52 Wk Low/High||0.18 / 2.20|
I continue to believe that biotech and biopharma stocks will outperform in 2018.
The South San Francisco, Calif.-based firm said after the market close on Tuesday that the FDA has extended the review period for the company's prior approval supplement for Bevyxxa (betrixaban).
The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.
The Fremont, Calif.-based firm has unveiled positive results from its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation.
Synergy Pharmaceuticals, Trevena and Egalet seem to have worst-case scenarios priced into them.
A look at how lawsuits and FDA changes could impact the industry.
Readers want to know what to do with the two biotech names, which are headed in opposite directions.
Trevena's oliceridine seeks to provide the pain relief of morphine with less side effects.
Not much change in the market since our last update. The S&P 500 and Dow are down, and the NASDAQ is having a nice day. Longtime favorite Cara Therapeutics continues its huge run, up another 20% plus today. But I can't find any new news to support t...
The bears had a good opportunity early on but did nothing with it, though buyers gained little traction.
Not a big day of gains, but there is underlying support.
Wal-Mart sets the tone, but selling hasn't been bad enough to kill rally.
We have a few more days of this slow trading, and it is unlikely to change much.
Signs of support on the S&P, but there is a lot of uncertainty.